EMA's Latest Approval Could Change Care for Rare Muscle Disorder

The global pharma company Lupin Limited has announced their latest drug approval by the EMA could create a great shift in Non-dystrophic myotonic disorders, which are a rare muscle disorder. 

The European Medicines Agency has approved the marketing authorization for the drug named NaMuscla, which is supported by the Pediatric Investigation Plan (PIP). This helps Lupin in expanding the target patient base and extending the market exclusivity in Europe. 

This includes Lupin's drug among other orphan drugs, positioning it as one of the only approved drugs in the market for myotonia and non-dystrophic myotonia disorder across all age groups.

What are Non-dystrophic myotonic disorders? 

The non-dystrophic myotonias are a rare genetic condition where the muscles have trouble relaxing after movement. For instance, when we grip something or make a fist, the muscle gets tightened, and for someone with this condition can’t relax back, as their muscle gets locked for a few seconds. 

The muscles in our body rely on sodium and chloride channels for tiny electrical signals. With these conditions, the genetic causes will stay switched on and won’t be able to relax back to their old positions. 

Also Read: Pharmaceutical 4.0: Redefines Compliance, Automation & AI 

There are two types of conditions: 

• In the first type, the condition is likely to get better with movement; the person will feel stiffness in the first movement, but they repeat it is likely to fade away. 

• Whereas in the second type, the condition will get worse with movement and cold, as it will make the muscles tighter. Cold weather, cold water, or eating food with potassium levels can trigger the condition. 

NaMuscla with New Dosage 

The current approval of NaMuscla includes two new dosages of 62mg and 83mg capsules, in addition to the existing 167mg capsules. This revised indication of the medicine will cover symptomatic treatment of myotonia in children aged 6-11 years, adolescents aged 12-17 years, and adults aged 18 years and above with non-dystrophic myotonic disorders. 

Therefore, NaMuscla appears to be a milestone drug that helps in curing adults and provides comprehensive treatment for pediatric populations. It also comes with a specific pediatric framework with standard dosages of 62mg and 83mg. 

Globally, 1 in a million people are affected by rare conditions of non-dystrophic myotonia. As of now, there are specific numbers of myotonia cases in India. But this new approval is marked as a great achievement for a rare muscle condition. 

Lupin Limited is a popular innovation-led multinational pharmaceutical company that is focused on inventing life-saving drugs. It is also now focused on coming up with new dosage strengths that will expand pediatric indications available across Europe.